Emerging role of multikinase inhibitors for refractory thyroid cancer

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 257-265

  Perez, Cesar A ^a   Arango, Belisario A ^a   Velez, Michel ^a   Raez, Luis E ^b   Santos, Edgardo S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Memorial Health Care System   (United States)

Author keywords

Axitinib; Cabozantinib; Lenvatinib; Mitogen activated protein kinase (MAPK); Motesanib; Pazopanib; Thyroid cancer; Vandetanib; Vascular endothelial growth factor receptor 2 (VEGFR2)

Indexed keywords

AXITINIB; B RAF KINASE; BORTEZOMIB; CABOZANTINIB; IMATINIB; LENVATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PROTEIN RET; RAF PROTEIN; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN;

ADVANCED CANCER; ANOREXIA; ARTHRALGIA; ASTHENIA; CALCITONIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EDEMA; ENZYME ACTIVITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOPIGMENTATION; KERATOACANTHOMA; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; LUNG HEMORRHAGE; METASTASIS; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PROTEIN FUNCTION; PROTEINURIA; PROTO ONCOGENE; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 84866767780     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S24465     Document Type: Review

References (55)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):313-319.
3. Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med. 1974;290(4):193-197.
4. Shimaoka K, Schoenfeld D, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56(9):2155-2160.
5. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96(11):3390-3397.
6. Commander H, Whiteside G, Perry C. Vandetanib: first global approval. Drugs. 2011;71(10):1355-1365.
7. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291-3310.
8. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245-262.
9. Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res. 2009;15(2):485-491.
10. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(11):4085-4090.
11. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373-6379.
12. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17(11):1359-1370.
13. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19): 2039-2049.
14. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999;155(6): 1967-1976.
15. Klein M, Picard E, Vignaud JM, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol. 1999;161(1):41-49.
16. Lennard CM, Patel A, Wilson J, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery. 2001;129(5):552-558.
17. Mologni L. Development of RET kinase inhibitors for targeted cancer therapy. Curr Med Chem. 2011;18(2):162-175.
18. Houvras Y. Completing the arc: targeted inhibition of RET in medullary thyroid cancer. J Clin Oncol. 2012;30(2):200-202.
19. Langmuir PB, Yver A. Clin Pharmacol Ther. 2012 Jan;91(1):71-80
20. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767-772.
21. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95(6):2664-2671.
22. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134-141.
23. Gramza AW, Wells SA, Balasubramaniam S, Fojo AT. Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: phase I results [abstract]. J Clin Oncol. 2011;29 Suppl:5565.
24. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068.
25. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962-972.
26. Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) [abstract]. J Clin Oncol. 2011;29 Suppl:5503.
27. Shumaker R, Zhou M, Ren M, Fan J, Martinez G, Darpo B. Lenvatinib (E7080) does not prolong the QTc interval: results from a thorough QT study in healthy volunteers [abstract]. Mol Cancer Ther. 2011; 10(11 Suppl 1):C116.
28. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675-1684.
29. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714-4719.
30. Brose MS, Troxel AB, Redlinger M, et al. Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients [abstract]. J Clin Oncol. 2009;27(Suppl 15):6002.
31. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28(14): 2323-2330.
32. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25(17):2369-2376.
33. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31-42.
34. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27(23):3794-3801.
35. Bass MB, Sherman SI, Schlumberger MJ, et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab. 2010;95(11):5018-5027.
36. Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer [abstract]. J Clin Oncol. 2008;26 Suppl: 6025.
37. Goulart B, Carr L, Martins RG, et al. Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC) [abstract]. J Clin Oncol. 2008;26 Suppl:6062.
38. Ravaud A, de la Fouchardiere C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial [abstract]. J Clin Oncol. 2008;26 Suppl:6058.
39. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165(1):35-52.
40. Mancuso MR, Davias R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116(10):2610-2621.
41. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290(2):H560-H576.
42. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006;290(2):H547-H559.
43. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetics and clinical results. J Clin Oncol. 2005;23(24):5474-5483.
44. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708-4713.
45. Joly AH. Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic and anti-tumor effects. Eur J Cancer. 2006; Suppl 4:35.
46. Sennino B, Naylor RM, Tabruyn SP, You WK, Aftab DT, McDonald DM. Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184 [abstract]. Mol Cancer Ther. 2011;8(12 Suppl 1):A13.
47. Kurzrock R, Sherman S, Hong DS, et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC). Paper presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 21-24, 2008; Geneva, Switzerland.
48. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
49. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal tumors. N Engl J Med. 2002;347(7):472-480.
50. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myelogenous leukemia. N Engl J Med. 2003;348(11):994-1004.
51. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for this molecular target. Results from the EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39(14):2006-2011.
52. Sawyers CL. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J Clin Oncol. 2002;20(17):3568-3569.
53. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-566.
54. de Groot JWB, Zonnenberg BA, Quarles van Ufford-Mannesse P, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(9):3466-3469.
55. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol. 2007;157(2):215-220.